Skip to content
10-Q

Quarterly Report

ARCUTIS BIOTHERAPEUTICS, INC. ARQT

0001787306-26-000040

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 125.08M sh
Shares Diluted Q1 2026 · Mar 31, 2026 129.37K sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 126.04K sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $608K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $2.24M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$30.38M
Long Term Debt Q1 2026 · Mar 31, 2026 $101.47M
Long Term Debt Q1 2026 · Dec 31, 2025 $107.96M
Short Term Debt Q1 2026 · Mar 31, 2026 $7.95M
Short Term Debt Q1 2026 · Dec 31, 2025 $1M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $34.76M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $42.91M
Stockholders Equity Q1 2026 · Mar 31, 2026 $189.65M
Stockholders Equity Q1 2026 · Dec 31, 2025 $189.48M
Stockholders Equity Q1 2026 · Mar 31, 2025 $142.66M
Stockholders Equity Q1 2026 · Dec 31, 2024 $157.54M
Current Liabilities Q1 2026 · Mar 31, 2026 $163.2M
Current Liabilities Q1 2026 · Dec 31, 2025 $129.84M
Total Liabilities Q1 2026 · Mar 31, 2026 $270.36M
Total Liabilities Q1 2026 · Dec 31, 2025 $243.49M
Current Assets Q1 2026 · Mar 31, 2026 $438.06M
Current Assets Q1 2026 · Dec 31, 2025 $411.23M
Total Assets Q1 2026 · Mar 31, 2026 $460M
Total Assets Q1 2026 · Dec 31, 2025 $432.97M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.09
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.20
Eps Basic Q1 2026 · Mar 31, 2026 −$0.09
Eps Basic Q1 2026 · Mar 31, 2025 −$0.20
Sga Expense Q1 2026 · Mar 31, 2026 $74.08M
Sga Expense Q1 2026 · Mar 31, 2025 $64M
Rd Expense Q1 2026 · Mar 31, 2026 $30.63M
Rd Expense Q1 2026 · Mar 31, 2025 $17.54M
Net Income Q1 2026 · Mar 31, 2026 −$11.3M
Net Income Q1 2026 · Mar 31, 2025 −$25.06M
Operating Income Q1 2026 · Mar 31, 2026 −$9.09M
Operating Income Q1 2026 · Mar 31, 2025 −$24.53M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $9.78M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $8.83M
Revenue Q1 2026 · Mar 31, 2026 $105.4M
Revenue Q1 2026 · Mar 31, 2025 $65.85M